Streetwise Reports' Article Archives — February 2019 back to current month (14)
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report.
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report.
The arrangement represents this Canadian life sciences firm's entrée into a significant market.
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate.
Canadian Company Completes Two Cannabis Harvests (02/17/2019)
The firm also makes progress in obtaining technology rights and various licenses.
Bringing Advanced Technology to the Cannabis Space (02/13/2019)
This cannabis technology company brings artificial intelligence, blockchain and cryptocurrency to the global medical cannabis marketplace to help patients make informed decisions and drive medical cannabis sales.
The Canadian company continues seeking partners to leverage its discovery and development platform.
A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report.
Analyst expects "transformational year" for company with a phase 3 trial underway.
An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study.
This new machine takes the company's product line count to four.
Is Elixinol the Fastest Growing Hemp/CBD Producer? (02/04/2019)
Fincom Investment Partners discusses Elixinol's Q4 earnings, previews Charlotte's Web and CV Sciences' earnings, and compares the three companies.
This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note.
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings.
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|